Second alternative-donor haploidentical stem cell transplantation enhances survival in patients with myeloid malignancies complicated by posttransplant human leukocyte antigen loss relapse [0.03%]
第二次供者淋巴细胞输注可提高HLA半相合移植后复发患者的生存率
Xiao-Tong Chen,Ze-Chang Shi,Yu Wang et al.
Xiao-Tong Chen et al.
Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy [0.03%]
TP53改变对CD19-CART细胞治疗后复发/难治B细胞急性淋巴细胞白血病的儿科和年轻成人患者的预后的影响
Anna Alonso-Saladrigues,Elena Esperanza-Cebollada,Clara Vicente-Garcés et al.
Anna Alonso-Saladrigues et al.
Relapse remains the leading cause of treatment failure in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy. While prognos...
Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment [0.03%]
供者年龄对轻度认知障碍造血干细胞移植患者认知恢复的影响
Matthew A Bergens,Matthew Braun,Ernaya J Johnson et al.
Matthew A Bergens et al.
Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation [0.03%]
allo-HSCT后复发的急性髓系白血病患者的突变图谱变化
Kristina Maas-Bauer,Thomas Meyer,Mehtap Yücel et al.
Kristina Maas-Bauer et al.
Relapse of acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation (allo-HCT) remains a life-threatening complication and is influenced by the underlying biology of the AML and possibly by genetic alterations. I...
Outcomes of hematopoietic stem cell transplantation in patients aged 70 years and older [0.03%]
老年患者造血干细胞移植的结局分析
Rachel B Gorham,Salyka Sengsayadeth,Christina A Snider et al.
Rachel B Gorham et al.
Twelve-year utilization and outcomes of haploidentical hematopoietic stem cell transplantation (HSCT) in the Eastern Mediterranean (EM) region: A multicenter EMBMT registry analysis [0.03%]
东地中海地区造血干细胞移植(HSCT)12年利用情况和预后：EMBMTR注册中心分析结果
Jean El Cheikh,Ali Tarhini,Ali Bazarbachi et al.
Jean El Cheikh et al.
Haploidentical hematopoietic stem cell transplant (Haplo-HSCT) has emerged as an alternative for patients lacking matched human leukocyte antigen (HLA) donors. The scarcity of stem cell donor registries and cord banks across the Eastern Med...
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee [0.03%]
异基因造血细胞移植后骨髓衰竭性疾病缓解和复发的定义及改善移植结局的优化：EBMT实践协调与指南委员会的推荐意见
Christopher Armstrong,Kavita Raj,Giorgia Battipaglia et al.
Christopher Armstrong et al.
Myelodysplastic/myeloproliferative neoplasms (excluding CMML) are rare and heterogenous malignancies with recurrent and overlapping clinicopathological abnormalities. Classification and characterization continue to evolve, but outcomes rema...
IPSS-M downstaging before transplantation does not improve the prognosis of patients with myelodysplastic neoplasms [0.03%]
移植前的IPSS-M期别降低并不能改善骨髓增生异常肿瘤患者的预后
T Richardson,D Schütte,P Gödel et al.
T Richardson et al.
Allogeneic hematopoietic cell transplantation (ASCT) is the only curative option for patients with myelodysplastic syndromes (MDS), but whether cytoreductive pretreatment and molecular "downstaging" according to the IPSS-M improves outcomes...
Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT [0.03%]
桥接CAR-T前的治疗：EBMT的CMWP和CTIWP调查结果摘要
Nico Gagelmann,Maximilian Merz,Laurien G A Baaij et al.
Nico Gagelmann et al.
Correction: Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease [0.03%]
纠正：Belumosudil和Belumosudil/Ruxolitinib联合治疗糖皮质激素难治性慢性移植物抗宿主病的现实世界经验
Gagan Raju,Moneeza Walji,David Nemirovsky et al.
Gagan Raju et al.
Published Erratum
Bone marrow transplantation. 2026 Mar 30. DOI:10.1038/s41409-026-02822-3 2026